CD7 and myasthenia gravis: Similarly, in rheumatoid arthritis (RA), myasthenia gravis (MG), neuromyelitis optical spectrum disorders (NMOSDs), idiopathic inflammatory myositis, and Crohn’s disease, CAR-T therapies targeting CD19+, CD7, and CD20+ B cells are being explored to reduce autoantibody production and alleviate disease symptoms [40].